

The effect of non-steroidal anti-inflammatory drugs on bleeding, platelet function and consumption of opiates following cardiac surgery

Submission date 07/04/2018	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 25/04/2018	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 30/03/2020	Condition category Surgery	☐ Individual participant data

Plain English summary of protocol

Background and study aims

The pain following heart surgery is mostly associated with sternotomy (surgical procedure to divide the sternum), pericardiectomy (removal of the membrane around the heart), chest tube insertion, and the removal of a vein from a patient's leg. Traditionally, intravenous opioids are used for pain management after heart surgery.

However, their use is associated with side effects, such as nausea, vomiting, itching, urinary retention, intestinal paresis, and respiratory depression. Long-acting opioids administered after surgery postpone the removal of the ventilation tube in the windpipe (extubation) due to increased sedation and respiratory depression (inadequate slow and shallow breathing).

A combination of nonsteroidal anti-inflammatory drugs (NSAID) and opioid analgesics has been recommended for pain relief after major surgeries. The need of opioid analgesics can be reduced by using NSAIDs, thus also reducing the side effects of opioid analgesics, especially nausea and vomiting. The combination of NSAID and opioid analgesics contributes to an earlier extubation and patient mobilisation leading to an early discharge from the ICU.

The aim of the study is to confirm whether NSAID diclofenac decreases the use of opioid analgesics following cardiac surgery during the first 20 hours after surgery.

Who can participate?

Adults aged 20 – 85 years undergoing elective cardiac surgery

What does the study involve?

Participants are randomly allocated to one of two groups. Those in the first group receive intravenous Diclofenac after cardiac surgery, whilst those in the control group receive intravenous saline. Participants are followed up for 20 hours after surgery.

What are the possible benefits and risks of participating?

There are no specific benefits or risks for those taking part in the study.

Where is the study run from?
University Medical Centre Maribor (Slovenia)

When is the study starting and how long is it expected to run for?
May 2016 to December 2018

Who is funding the study?
University Medical Centre Maribor (Slovenia)

Who is the main contact?
Mrs Irena Osojnik (Scientific)
irena.ogrizek@guest.arnes.si

Contact information

Type(s)
Scientific

Contact name
Mrs Irena Osojnik

Contact details
University Medical Centre Maribor
Ljubljanska ulica 5
Maribor
Slovenia
2000
+ 386 51 243 260
irena.ogrizek@guest.arnes.si

Additional identifiers

Protocol serial number
0120-430/2016-2

Study information

Scientific Title
The effect of diclofenac on bleeding, platelet function, and the use of opiates following coronary artery bypass graft

Study objectives
The purpose of the study is to establish whether using diclofenac after a coronary artery bypass graft (CABG) with extracorporeal circuit decreases the consumption of opioid analgesics and their side effects. It also aims to establish whether diclofenac disrupts the platelet function and consequently increases bleeding and transfusion of blood and blood products after cardiac surgery.

Ethics approval required
Old ethics approval format

Ethics approval(s)

1. Commission of the Republic of Slovenia for Medical Ethics (Komisija Republike Slovenije za medicinsko etiko), 22/08/16, ref: 0120-430
2. Republic of Slovenia National Medical Ethics Committee (NMEC) 10/08/2016, ref: 2016-2

Primary study design

Interventional

Study design

Single-centre prospective randomised controlled study

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Cardiac surgery

Interventions

After cardiac surgery, participants are randomised to one of two treatment groups using coin randomisation.

1. The treatment group receive an intravenous infusion of 75 mg diclofenac (250 ml Neodolpasse) within 90 minutes to three hours after cardiac surgery, and again after 12 hours.
2. The control group receive an infusion of 250 ml of saline (0.9% NaCl) within 90 minutes to three hours after surgery, and again after 12 hours.

Both groups are followed up 20 hours after surgery.

Both groups receive intravenous bolus piritramid 0.05 mg/kg body weight every six hours for postoperative pain relief. In addition to basal pain relief the patients receive additional piritramid 0.025 mg/kg on request by means of nurse controlled analgesia to achieve adequate analgesia (NRS $\leq$ 3).

Intervention Type

Drug

Drug/device/biological/vaccine name(s)

Diclofenac

Primary outcome(s)

1. Pain is measured using the NRS (numerical rating scale) for pain assessment at 1 hour intervals until 20 hours after surgery
2. The use of piritramide is recorded within the first 20 hours after surgery
3. The use of blood and blood product is recorded within the first 20 hours after surgery

Key secondary outcome(s)

1. Haemodynamic data (invasive blood pressure and heart rate) is measured using Phillips MX 800 monitor at 1 hour intervals until 20 hours after surgery
2. Sternal drain blood loss is measured using Sternal drainage system Atrium at 1 hour intervals until 20 hours after surgery
3. Time to extubation and time of ICU stay is recorded.
4. Unfavourable side effects are recorded during the ICU stay

Completion date

30/12/2018

Eligibility

Key inclusion criteria

1. Adult aged 20 - 85 years
2. Operated for elective cardiac surgery using extracorporeal circuit

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Total final enrolment

72

Key exclusion criteria

1. History of peptic ulcer disease, gastrointestinal bleeding
2. Renal and liver insufficiency
3. Allergy for nonsteroidal analgetics
4. Increased bleeding during surgery
5. Increased bleeding after surgery, as defined by the chest tube drainage of more than 300 ml per hour during the first 3 hours after surgery.

Date of first enrolment

30/10/2016

Date of final enrolment

30/08/2018

Locations

Countries of recruitment

Slovenia

Study participating centre

University Medical Centre Maribor

Maribor

Slovenia

+386 51 243 260

Sponsor information

Organisation

University Medical Centre Maribor

ROR

<https://ror.org/02rjj7s91>

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

University Medical Centre Maribor

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request.

Additional documents are available upon request from the author.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	07/11/2019	30/03/2020	Yes	No